Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Free Cash Flow (2020 - 2024)

Immuneering (IMRX) has 5 years of Free Cash Flow data on record, last reported at -$14.5 million in Q4 2024.

  • For Q4 2024, Free Cash Flow fell 21.54% year-over-year to -$14.5 million; the TTM value through Dec 2024 reached -$55.1 million, down 11.71%, while the annual FY2024 figure was -$55.1 million, 11.71% down from the prior year.
  • Free Cash Flow reached -$14.5 million in Q4 2024 per IMRX's latest filing, down from -$13.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$3.5 million in Q3 2020 and bottomed at -$15.5 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$10.5 million, with a median of -$11.3 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: tumbled 159.08% in 2021, then decreased 1.08% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$5.5 million in 2020, then plummeted by 68.49% to -$9.3 million in 2021, then fell by 27.73% to -$11.8 million in 2022, then decreased by 1.08% to -$11.9 million in 2023, then decreased by 21.54% to -$14.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$14.5 million in Q4 2024, -$13.5 million in Q3 2024, and -$11.6 million in Q2 2024.